SavedAdd your journal

Journals / Gülhane Tıp Dergisi / 2017 / Cilt: 59 - Sayı: 2

Utility of FDG-PET/CT in primary central nervous system lymphoma and its contribution to prognosis estimation

FDG-PET\BT'nin primer santral sinir sistemi lenfomasında yararı ve prognoz tahminindeki katkısı

Kürşat OKUYUCU
ENGİN ALAGÖZ
Pages
44–48
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results:mean overall survival (Os) and disease-free survival (DFs) was 22.7 months, 16.8 months, respectively. mean sUVmax was 19.9 ± 6.7 in recurrent/metastatic group, 15.3 ± 7.2 in nonmetastatic (complete remission) group.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aims: Primary central nervous system lymphoma (PCNsL) is an aggressive form of extra-nodal non-Hodgkin's lymphoma confined to CNs at initial presentation.
📊
Key Findings & Data:This study was conducted to summarize the utility of FDG-PET/CT in the management of PCNsL and show its contribution to predicting survival.materials and methods: This study included 19 patients with PCNsL treated with high dose methotrexate between 2004 and 2015.
💡
Conclusion & Impact:Results:mean overall survival (Os) and disease-free survival (DFs) was 22.7 months, 16.8 months, respectively. mean sUVmax was 19.9 ± 6.7 in recurrent/metastatic group, 15.3 ± 7.2 in nonmetastatic (complete remission) group.
🔬Design:Review & Systematic Survey
📍Scope:2004 Verileri
⚙️Variables:Domain Parameters

Abstract

Aims: Primary central nervous system lymphoma (PCNsL) is an aggressive form of extra-nodal non-Hodgkin's lymphoma confined to CNs at initial presentation. The role of FDG-PET/CT in PCNsL is not fully defined and reviewed systematically. This study was conducted to summarize the utility of FDG-PET/CT in the management of PCNsL and show its contribution to predicting survival.materials and methods: This study included 19 patients with PCNsL treated with high dose methotrexate between 2004 and 2015. We retrospectively examined PET/CT and outcome of the patients. maximum standardized uptake value (sUVmax) was calculated. Results:mean overall survival (Os) and disease-free survival (DFs) was 22.7 months, 16.8 months, respectively. mean sUVmax was 19.9 ± 6.7 in recurrent/metastatic group, 15.3 ± 7.2 in nonmetastatic (complete remission) group. There was a statistically significant difference between them according to sUVmax values (p=0.199). Os at 1st year was 84%, 58% at 2nd year. DFs at first year was 47%, 31.5% at second year. Conclusion: The utility of FDG-PET/CT can be summarized as initial diagnosis, baseline staging and restaging, evaluation of treatment response and prognosis estimation in PCNsL. sUVmax derived from FDG-PET/CT is a strong predictor for progression and survival of the disease.

Özet

Amaç:Primer santral sinir sistemi lenfoması (PsssL) başlangıcında santral sinir sistemine hapsolmuş agresif bir ekstranodal non-Hodgkin lenfomadır. FDG-PET/CT'nin hastalıktaki rolü tam anlamıyla tanımlanmamış ve sistemik olarak gözden geçirilmemiştir. Bu çalışma, FDG-PET/CT'nin hastalığın yönetimindeki faydalarını özetlemek ve sağkalım tahminine katkısını göstermek için yapılmıştır. Gereç ve Yöntem: Bu çalışma 2004-2015 yılları arasında yüksek doz metotreksatla tedavi edilmiş 19 PsssL hastasını içermektedir. Geriye dönük olarak bu hastaların PET/CT sonuçlarını ve gidişatlarını inceledik. maksimum standardize tutulum değerleri (sUVmax) hesaplandı.Bulgular: Ortalama toplam sağkalım (Os) ve hastalıksız sağkalım (DFs) süreleri 22.7 ay ve 16.8 aydı. Ortalama sUVmax rekürrent/metastatik grupta 19.9 ± 6.7, nonmetastatik grupta 15.3 ± 7.2 idi. Bu iki grup arasında sUVmax değerlerine göre istatistiki olarak anlamlı bir fark mevcuttu (p=0.199). Os 1. yılda %84, 2. yılda %58; DFs 1. yılda %47, 2. yılda %31.5 idi. Sonuç:FDG-PET/CT'nin PsssL'deki kullanılabilirliği ilk teşhis, başlangıç ve yeniden evreleme, tedaviye yanıtın değerlendirilmesi ve prognoz tahmini şeklinde özetlenebilir. FDG-PET/CT görüntülerinden hesaplanan sUVmax, progresyon ve sağkalım tahmini açısından kuvvetli bir parametredir.

🔖

Cite This Article

OKUYUCU, K., ALAGÖZ, E. (2017). Utility of FDG-PET/CT in primary central nervous system lymphoma and its contribution to prognosis estimation. Gülhane Tıp Dergisi, Cilt: 59 - Sayı: 2, 44–48. https://ajindex.com/articles/173551

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Ambady P, Fu R, Netto JP, et al. Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease. Fluids Barriers CNS. 2017; 14: 16
  2. Kawai N, Miyake K, Yamamoto Y, Nishiyama Y, Tamiya T. 18F-FDG PET in the diagnosis and treatment of primary central nervous system lymphoma. Biomed Res Int. 2013; 2013: 247152
  3. Hoang-Xuan K, Bessell E, Bromberg J, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncol. 2015;16:e322-e332
  4. Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010; 11: 1036-1047
  5. Ambady P, Holdhoff M, Bonekamp D, Wong F, Grossman SA. Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy. CNS Oncol. 2015; 4: 393-398
  6. Kosaka N, Tsuchida T, Uematsu H, Kimura H, Okazawa H, Itoh H. 18F-FDG PET of common enhancing malignant brain tumors. AJR Am J Roentgenol. 2008; 190: W365-W369
  7. Okuyucu K, Ozaydın S, Alagoz E, et al. Prognosis estimation under the light of metabolic tumor parameters on initial FDG-PET/CT in patients with primary extranodal lymphoma. Radiol Oncol. 2016; 50: 360-369
  8. Arslan N, Tuncel M, Kuzhan O, et al. Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-D-glucose wit positron emission tomography in patients with small cell lung cancer. Ann Nucl Med. 2011; 25: 406-413
  9. Jahnke K, Thiel E, Martus P, et al; German Primary Central Nervous System Lymphoma Study Group. Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol. 2006; 80: 159-165
  10. Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases. Journal of Neurosurg. 2000; 92: 261-266
  11. Haldorsen IS, Krakenes J, Krossnes BK, Mella O, Espeland A. CT and MR imaging features of primary central nervous system lymphoma in Norway, 1989- 2003. AJNR Am J Neuroradiol. 2009; 30: 744-751
  12. Rosenfeld SS, Hoffman JM, Coleman RE, Glantz MJ, Hanson MW, Schold SC. Studies of primary central nervous system lymphoma with fluorine-18- fluorodeoxyglucose positron emission tomography. J Nucl Med. 1992; 33: 532-536